Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANF NASDAQ:CELZ NASDAQ:GNPX NASDAQ:PMCB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$3.38+0.6%$3.20$2.83▼$23.40$2.21M1.09725,699 shs11,041 shsCELZCreative Medical Technology$2.32+2.7%$2.17$1.50▼$6.25$8.59M1.8766,238 shs58,587 shsGNPXGenprex$0.78-1.8%$1.21$0.74▼$55.00$8.26M-0.94936,328 shs200,610 shsPMCBNuvilex$0.82-4.0%$0.74$0.63▼$1.51$8.84M0.46228,792 shs110,697 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma+0.30%-2.33%+15.46%-29.26%-84.23%CELZCreative Medical Technology-2.16%-1.74%+1.35%+24.86%+14.72%GNPXGenprex+2.37%-2.49%-14.10%-60.27%-94.33%PMCBNuvilex+12.80%+7.69%+12.80%+24.23%-19.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$3.38+0.6%$3.20$2.83▼$23.40$2.21M1.09725,699 shs11,041 shsCELZCreative Medical Technology$2.32+2.7%$2.17$1.50▼$6.25$8.59M1.8766,238 shs58,587 shsGNPXGenprex$0.78-1.8%$1.21$0.74▼$55.00$8.26M-0.94936,328 shs200,610 shsPMCBNuvilex$0.82-4.0%$0.74$0.63▼$1.51$8.84M0.46228,792 shs110,697 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma+0.30%-2.33%+15.46%-29.26%-84.23%CELZCreative Medical Technology-2.16%-1.74%+1.35%+24.86%+14.72%GNPXGenprex+2.37%-2.49%-14.10%-60.27%-94.33%PMCBNuvilex+12.80%+7.69%+12.80%+24.23%-19.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 2.67Moderate Buy$42.501,157.40% UpsideCELZCreative Medical Technology 1.50ReduceN/AN/AGNPXGenprex 1.00SellN/AN/APMCBNuvilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CANF, CELZ, PMCB, and GNPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026CELZCreative Medical Technology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/13/2026CANFCan-Fite BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/13/2026CANFCan-Fite BioPharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy5/12/2026CANFCan-Fite BioPharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$2.50 ➝ $5.004/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PMCBNuvilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$405K5.47N/AN/A$1.76 per share1.92CELZCreative Medical Technology$10K851.00N/AN/A$1.66 per share1.39GNPXGenprexN/AN/AN/AN/A$1.60 per shareN/APMCBNuvilexN/AN/AN/AN/A$7.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$35.80N/AN/AN/AN/AN/AN/AN/ACELZCreative Medical Technology-$5.99M-$2.14N/AN/AN/AN/A-88.38%-84.71%8/14/2026 (Estimated)GNPXGenprex-$16.23M-$14.14N/AN/AN/AN/A-247.32%-176.73%N/APMCBNuvilex$30.66M-$1.12N/AN/AN/AN/A2.13%1.69%7/1/2026 (Estimated)Latest CANF, CELZ, PMCB, and GNPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026GNPXGenprexN/A-$0.64N/A-$0.64N/AN/A5/8/2026Q1 2026CELZCreative Medical Technology-$0.39-$0.38+$0.01-$0.38$0.00 millionN/A3/20/2026Q4 2025CELZCreative Medical Technology-$0.37-$0.80-$0.43-$0.80N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACELZCreative Medical TechnologyN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/ACELZCreative Medical TechnologyN/A19.6719.67GNPXGenprexN/A5.615.61PMCBNuvilexN/A12.3312.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%CELZCreative Medical Technology1.42%GNPXGenprex14.05%PMCBNuvilex34.24%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%CELZCreative Medical Technology1.70%GNPXGenprex0.25%PMCBNuvilex10.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma8655,000N/ANot OptionableCELZCreative Medical Technology53.70 million3.63 millionNot OptionableGNPXGenprex2010.59 million10.56 millionNo DataPMCBNuvilex410.74 million9.56 millionOptionableCANF, CELZ, PMCB, and GNPX HeadlinesRecent News About These CompaniesNuvilex Inc. (NASDAQ:PMCB) Sees Large Increase in Short InterestMay 29 at 4:31 AM | americanbankingnews.comNuvilex (NASDAQ:PMCB) Trading Down 3.3% - Time to Sell?May 28 at 2:37 AM | americanbankingnews.comInsider Buying: Nuvilex (NASDAQ:PMCB) Director Acquires 20,000 Shares of StockJanuary 8, 2026 | insidertrades.comPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsSeptember 2, 2025 | businesswire.comPharmaCyte Biotech, Inc. Announces Closing of $7 Million FinancingAugust 20, 2025 | businesswire.comPharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing InvestorsAugust 18, 2025 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comPharmaCyte Biotech Inc PMCBDecember 5, 2023 | morningstar.comMWith biotech in a slump, the industry’s job market is upside downNovember 28, 2023 | statnews.comSThe return of biotech’s “bump factor” amid an economic downturnNovember 24, 2023 | statnews.comSPharmaCyte Biotech: Entry Into A Material Definitive Agreement, Other Events, Financial Statements And ExhibitsNovember 18, 2023 | cbonds.comCPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | markets.businessinsider.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechNovember 15, 2023 | finance.yahoo.comBiotech power broker John Maraganore offers advice to the next crop of entrepreneursOctober 23, 2023 | statnews.comSPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | msn.comPharmaCyte Biotech Announces Final Results of Tender OfferJune 15, 2023 | finance.yahoo.comLos Angeles Biotech NewsJune 14, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANF, CELZ, PMCB, and GNPX Company DescriptionsCan-Fite BioPharma NYSE:CANF$3.38 +0.02 (+0.60%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Creative Medical Technology NASDAQ:CELZ$2.32 +0.06 (+2.70%) As of 02:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Genprex NASDAQ:GNPX$0.78 -0.01 (-1.85%) As of 02:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Nuvilex NASDAQ:PMCB$0.82 -0.03 (-4.00%) As of 02:08 PM Eastern This is a fair market value price provided by Massive. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar Tree Keeps Winning After Family Dollar Divorce Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Meta's Manus Mess: Why China Blocked the Deal and What It Means Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
